

Stephen C Rubin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8946874/publications.pdf>

Version: 2024-02-01

236
papers

16,519
citations

14655

66
h-index

16650

123
g-index

238
all docs

238
docs citations

238
times ranked

13790
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 159, 79-87.	1.4	6
2	Postoperative complications of epidural analgesia at hysterectomy for gynecologic malignancies: an analysis of the National Surgical Quality Improvement Program. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1203-1209.	2.5	9
3	Second primary anal and oropharyngeal cancers in cervical cancer survivors. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 478.e1-478.e6.	1.3	17
4	Second primary uterine malignancies after radiation therapy for cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 389-394.	1.7	11
5	Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1380-1390.	1.6	178
6	Randomized Clinical Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>Obstetrical and Gynecological Survey</i> , 2019, 74, 474-476.	0.4	0
7	Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 395-401.	0.9	2
8	Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2018, 149, 525-530.	1.4	24
9	Basic Principles of Chemotherapy. , 2018, , 449-469.e2.		8
10	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018, 24, 777-783.	7.0	171
11	A preoperative risk score to predict red blood cell transfusion in patients undergoing hysterectomy for ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 598.e1-598.e10.	1.3	12
12	Phase I study of carboplatin (C), pegylated liposomal doxorubicin (PLD) and everolimus (E) in platinum-sensitive epithelial ovarian, Fallopian tube or primary peritoneal cancer in first relapse (NCT01281514).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5580-5580.	1.6	0
13	Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 598-604.	1.3	4
14	CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. <i>Clinical Cancer Research</i> , 2017, 23, 3684-3691.	7.0	20
15	Bevacizumab and paclitaxel+carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 779-791.	10.7	460
16	National Cancer Database Report of Lymphadenectomy Trends in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1408-1415.	2.5	6
17	Group-based trajectory modeling of fear of disease recurrence among women recently diagnosed with gynecological cancers. <i>Psycho-Oncology</i> , 2017, 26, 1799-1809.	2.3	17
18	Blood Loss from Robotic Assisted Hysterectomy. <i>Journal of Gynecologic Surgery</i> , 2017, 33, 47-50.	0.1	0

#	ARTICLE	IF	CITATIONS
19	AWARE: Randomized study of an EMR-based intervention targeting hereditary cancer (CA) risk awareness in peri-op CA patients (pts).. Journal of Clinical Oncology, 2017, 35, e13119-e13119.	1.6	0
20	Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. Obstetrical and Gynecological Survey, 2016, 71, 344-345.	0.4	0
21	Disparities in the management and outcome of cervical cancer in the United States according to health insurance status. Gynecologic Oncology, 2016, 141, 516-523.	1.4	49
22	The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma. Gynecologic Oncology, 2016, 141, 434-439.	1.4	13
23	The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. International Journal of Gynecological Cancer, 2016, 26, 141-148.	2.5	24
24	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. New England Journal of Medicine, 2016, 374, 738-748.	27.0	303
25	Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. Cancer Nursing, 2015, 38, 375-382.	1.5	56
26	Emotion episodes during psychotherapy sessions among women newly diagnosed with gynecological cancers. Psycho-Oncology, 2015, 24, 1189-1196.	2.3	5
27	A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation â€” An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2015, 137, 386-391.	1.4	224
28	CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.. Journal of Clinical Oncology, 2015, 33, 5522-5522.	1.6	2
29	Quality of care for the initial management of stage IB1-IIA2 invasive cervical carcinomas.. Journal of Clinical Oncology, 2015, 33, e16596-e16596.	1.6	0
30	Cancer-Related Concerns Among Women With a New Diagnosis of Gynecological Cancer: An Exploration of Age Group Differences. International Journal of Gynecological Cancer, 2014, 24, 165-171.	2.5	10
31	Correlation of Pelvic Magnetic Resonance Imaging Diagnosis With Pathology for Indeterminate Adnexal Masses. International Journal of Gynecological Cancer, 2014, 24, 1215-1221.	2.5	10
32	Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Pagetâ€™s Disease. International Journal of Surgical Pathology, 2014, 22, 374-377.	0.8	3
33	The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1âˆ™ deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecologic Oncology, 2014, 133, 584-590.	1.4	15
34	Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology, 2014, 32, 1210-1217.	1.6	77
35	Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers. General Hospital Psychiatry, 2014, 36, 81-87.	2.4	30
36	Socialâ€™ cognitive processes associated with fear of recurrence among women newly diagnosed with gynecological cancers. Gynecologic Oncology, 2013, 128, 120-127.	1.4	53

#	ARTICLE	IF	CITATIONS
37	Basic Principles of Chemotherapy. , 2012, , 515-538.e2.		0
38	Therapist and patient perceptions of alliance and progress in psychological therapy for women diagnosed with gynecological cancers.. Journal of Consulting and Clinical Psychology, 2012, 80, 800-810.	2.0	13
39	A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study. Gynecologic Oncology, 2012, 127, 356-361.	1.4	19
40	Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma. Journal of Gynecologic Oncology, 2012, 23, 257.	2.2	8
41	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 2012, 61, 629-641.	4.2	109
42	Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: A clinically recalcitrant entity. Gynecologic Oncology, 2011, 120, 108-112.	1.4	32
43	Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology, 2011, 120, 464-469.	1.4	40
44	A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 2011, 121, 264-268.	1.4	21
45	Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology, 2011, 123, 19-26.	1.4	193
46	Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A gynecologic oncology group study. Gynecologic Oncology, 2011, 123, 182-186.	1.4	15
47	A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecologic Oncology, 2011, 123, 486-491.	1.4	59
48	Tissue-based immune monitoring II. Cancer Biology and Therapy, 2011, 12, 367-377.	3.4	21
49	Tissue-based immune monitoring I. Cancer Biology and Therapy, 2011, 12, 357-366.	3.4	10
50	Therapy processes and outcomes of psychological interventions for women diagnosed with gynecological cancers: A test of the generic process model of psychotherapy.. Journal of Consulting and Clinical Psychology, 2010, 78, 236-248.	2.0	17
51	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment, 2010, 124, 195-203.	2.5	58
52	Epithelial ovarian cancer in the elderly: The memorial sloan-kettering cancer center experience. Cancer, 2010, 71, 634-637.	4.1	64
53	Epidemiology, staging and clinical characteristics. , 2010, , 1-23.		0
54	A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 2009, 115, 215-220.	1.4	50

#	ARTICLE	IF	CITATIONS
55	Intraepithelial T cells and tumor proliferation. <i>Cancer</i> , 2009, 115, 2891-2902.	4.1	118
56	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 533-543.	2.5	732
57	Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 773-778.	2.5	11
58	Maintenance of certification in obstetrics and gynecology: The time has come. <i>Gynecologic Oncology</i> , 2008, 111, 389-390.	1.4	1
59	Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 83-89.	1.6	331
60	Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4151-4159.	1.6	84
61	Mediators of a coping and communication-enhancing intervention and a supportive counseling intervention among women diagnosed with gynecological cancers.. <i>Journal of Consulting and Clinical Psychology</i> , 2008, 76, 1034-1045.	2.0	31
62	Long-Term Trajectories of Psychological Adaptation Among Women Diagnosed With Gynecological Cancers. <i>Psychosomatic Medicine</i> , 2008, 70, 677-687.	2.0	30
63	Therapy and Prognosis of BRCA-Associated Ovarian Cancer. , 2008, , 117-127.		0
64	Coping and communication-enhancing intervention versus supportive counseling for women diagnosed with gynecological cancers.. <i>Journal of Consulting and Clinical Psychology</i> , 2007, 75, 615-628.	2.0	69
65	Risk of Colorectal Cancer in Women With a Prior Diagnosis of Gynecologic Malignancy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 291-296.	2.2	8
66	Hereditary Issues In Ovarian Cancer. , 2007, , 169-193.		0
67	Primary lymphomas of the cervix and uterus: The University of Pennsylvania's experience and a review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1894-1901.	1.3	70
68	Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. <i>Gynecologic Oncology</i> , 2006, 101, 140-142.	1.4	68
69	Phase II trial of weekly paclitaxel (80 mg/m ²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006, 101, 436-440.	1.4	205
70	Screening for ovarian cancer in the general population. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2006, 20, 307-320.	2.8	41
71	A Phase II Trial of Intraperitoneal Photodynamic Therapy for Patients with Peritoneal Carcinomatosis and Sarcomatosis. <i>Clinical Cancer Research</i> , 2006, 12, 2517-2525.	7.0	102
72	Estrogen Sulfation Genes, Hormone Replacement Therapy, and Endometrial Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1311-1320.	6.3	76

#	ARTICLE	IF	CITATIONS
73	Case-Control Study of Postmenopausal Hormone Replacement Therapy and Endometrial Cancer. American Journal of Epidemiology, 2006, 164, 775-786.	3.4	74
74	Vascular leukocytes contribute to tumor vascularization. Blood, 2005, 105, 679-681.	1.4	183
75	Ovarian Cancer Patients' Psychological Distress: The Role of Physical Impairment, Perceived Unsupportive Family and Friend Behaviors, Perceived Control, and Self-Esteem.. Health Psychology, 2005, 24, 143-152.	1.6	93
76	Women with a Prior Diagnosis of Breast Cancer Are Not at an Increased Risk for Subsequent Colorectal Cancer. American Journal of Gastroenterology, 2005, 100, 2759-2764.	0.4	16
77	Epidemiology, staging and clinical characteristics. , 2005, , 1-37.		0
78	Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma. New England Journal of Medicine, 2004, 351, 2489-2497.	27.0	366
79	Prevalence and Predictors of Psychological Distress Among Women With Ovarian Cancer. Journal of Clinical Oncology, 2004, 22, 919-926.	1.6	161
80	RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biology and Therapy, 2004, 3, 1283-1289.	3.4	18
81	Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With <i>BRCA1/2</i> Mutations: A Decision Analysis. Journal of Clinical Oncology, 2004, 22, 1045-1054.	1.6	150
82	Delayed Hemorrhage After Cervical Conization Unmasking Severe Factor XI Deficiency. Obstetrics and Gynecology, 2004, 104, 1189-1192.	2.4	8
83	Management of Intestinal Obstruction in the Terminal Patient and Management of Ascites. , 2004, , 727-741.		2
84	Vaginal Cuff Recurrence of Endometrial Cancer Treated by Laparoscopic-Assisted Vaginal Hysterectomy. Gynecologic Oncology, 2003, 88, 62-65.	1.4	54
85	BRCA-related ovarian carcinoma. Cancer, 2003, 97, 2127-2129.	4.1	17
86	Risk of colorectal cancer in women with a prior diagnosis of gynecological malignancy. Gastroenterology, 2003, 124, A419.	1.3	0
87	Women with a prior diagnosis of breast cancer are not at an increased risk for subsequent colorectal cancer. Gastroenterology, 2003, 124, A644-A645.	1.3	0
88	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine, 2003, 348, 203-213.	27.0	2,930
89	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochemical and Biophysical Research Communications, 2003, 303, 1169-1178.	2.1	101
90	BRCA1 and BRCA2 Mutations in Ovarian Carcinoma. , 2003, , 201-208.		0

#	ARTICLE	IF	CITATIONS
91	Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. <i>Clinical Cancer Research</i> , 2003, 9, 264-72.	7.0	43
92	TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 1517-27.	7.0	73
93	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. <i>American Journal of Pathology</i> , 2002, 161, 2295-2309.	3.8	129
94	Tumor-Associated Macrophages as a Source of Functional Dendritic Cells in Ovarian Cancer Patients. <i>Clinical Immunology</i> , 2002, 102, 291-301.	3.2	15
95	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. <i>Human Gene Therapy</i> , 2002, 13, 627-639.	2.7	65
96	Prophylactic oophorectomy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2002, 16, 597-609.	2.8	12
97	The Clinical Course of Deep Vein Thrombosis in Patients with Gynecologic Cancer. <i>Gynecologic Oncology</i> , 2002, 84, 67-71.	1.4	35
98	Prophylactic Oophorectomy Comes of Age. <i>Gynecologic Oncology</i> , 2002, 85, 395-396.	1.4	2
99	CYTOREDUCTIVE SURGERY FOR OVARIAN CANCER. <i>Surgical Clinics of North America</i> , 2001, 81, 871-883.	1.5	44
100	Second-look laparotomy for epithelial ovarian cancer: A reappraisal. <i>Current Oncology Reports</i> , 2001, 3, 11-18.	4.0	15
101	Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors. <i>Annals of Surgical Oncology</i> , 2001, 8, 65-71.	1.5	104
102	Survival of BRCA1 Negative Ovarian Cancer Patients Based on Family History. <i>Gynecologic Oncology</i> , 2001, 83, 109-114.	1.4	4
103	Cervical Cancer: Successes and Failures. <i>Ca-A Cancer Journal for Clinicians</i> , 2001, 51, 89-91.	329.8	6
104	Phase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors. <i>Annals of Surgical Oncology</i> , 2001, 8, 65-71.	1.5	1
105	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. <i>Cancer Gene Therapy</i> , 2000, 7, 275-283.	4.6	63
106	Prolonged Remission of Recurrent, Metastatic Placental Site Trophoblastic Tumor after Chemotherapy. <i>Gynecologic Oncology</i> , 2000, 76, 115-117.	1.4	26
107	Reply. <i>Gynecologic Oncology</i> , 2000, 78, 395.	1.4	0
108	Early ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2000, 1, 129-137.	3.0	6

#	ARTICLE	IF	CITATIONS
109	Occult Bilateral Involvement in Stage I Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1999, 72, 288-291.	1.4	74
110	Endometrial Carcinoma Associated with Pregnancy: A Report of Three Cases and Review of the Literature. <i>Gynecologic Oncology</i> , 1999, 74, 118-122.	1.4	52
111	Intestinal Obstruction in Advanced Ovarian Cancer: What Does the Patient Want?. <i>Gynecologic Oncology</i> , 1999, 75, 311-312.	1.4	21
112	Surgical management of ovarian cancer. , 1999, 17, 173-180.		13
113	Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. <i>Obstetrics and Gynecology</i> , 1999, 93, 21-24.	2.4	120
114	Ten-Year Follow-Up of Ovarian Cancer Patients After Second-Look Laparotomy With Negative Findings. <i>Obstetrics and Gynecology</i> , 1999, 93, 21-24.	2.4	72
115	Primary Peritoneal Carcinoma. <i>Obstetrical and Gynecological Survey</i> , 1999, 54, 323-335.	0.4	45
116	Endometrial Adenocarcinoma with Trophoblastic Differentiation. <i>Gynecologic Oncology</i> , 1998, 69, 74-77.	1.4	35
117	Clinical Characteristics of Clear Cell Carcinoma of the Ovary. <i>Gynecologic Oncology</i> , 1998, 70, 255-258.	1.4	146
118	Germline Mutations of theBRCA1andBRCA2Genes in a Breast and Ovarian Cancer Patient. <i>Gynecologic Oncology</i> , 1998, 70, 432-434.	1.4	30
119	BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 178, 670-677.	1.3	167
120	Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer. , 1998, 82, 152-158.		41
121	Allelotype analysis of uterine leiomyoma: Localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. <i>Molecular Carcinogenesis</i> , 1998, 23, 243-247.	2.7	31
122	Long-term complications of chemotherapy. <i>Primary Care Update for Ob/Gyns</i> , 1998, 5, 65-68.	0.1	1
123	Chemotherapy resistance in ovarian cancer: New molecular perspectives. <i>Obstetrics and Gynecology</i> , 1998, 91, 783-792.	2.4	49
124	BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum*1. <i>Obstetrics and Gynecology</i> , 1998, 92, 596-600.	2.4	72
125	Molecular Evidence for Multifocal Papillary Serous Carcinoma of the Peritoneum in Patients With Germline BRCA1 Mutations. <i>Journal of the National Cancer Institute</i> , 1998, 90, 841-845.	6.3	123
126	Chemoprevention of Hereditary Ovarian Cancer. <i>New England Journal of Medicine</i> , 1998, 339, 469-471.	27.0	16

#	ARTICLE	IF	CITATIONS
127	CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER. <i>Obstetrics and Gynecology</i> , 1998, 91, 783-792.	2.4	28
128	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. <i>Obstetrics and Gynecology</i> , 1998, 92, 596-600.	2.4	26
129	Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2620-2624.	1.6	133
130	Advances in cytoreductive surgery of gynecologic cancers. <i>Cancer Treatment and Research</i> , 1998, 95, 203-217.	0.5	1
131	Arterial Occlusions as a Presenting Feature of Acute Promyelocytic Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 436-437.	1.3	15
132	Modern treatment options in epithelial ovarian carcinoma. <i>Current Opinion in Obstetrics and Gynecology</i> , 1998, 10, 29-32.	2.0	6
133	Initial Surgical Management of Advanced Epithelial Ovarian Cancer. <i>Cancer Investigation</i> , 1997, 15, 270-276.	1.3	1
134	Effect of Surgical Debulking on Survival in Stage IV Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 64, 4-8.	1.4	93
135	Hereditary Ovarian Cancer: Molecular Genetics and Clinical Implications. <i>Gynecologic Oncology</i> , 1997, 64, 196-206.	1.4	113
136	Cycles of Dose-Intensive Chemotherapy with Peripheral Stem Cell Support in Persistent or Recurrent Platinum-Sensitive Ovarian Cancer. <i>Gynecologic Oncology</i> , 1997, 67, 272-276.	1.4	5
137	2197 The role of extended field radiation therapy in early stage cervical carcinoma with para-aortic metastases” A study of survival impact and complication rates. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 339.	0.8	0
138	An asymmetric, posterior spacing system for use with mini-ovoids in the treatment of carcinoma of the cervix. <i>International Journal of Gynecological Cancer</i> , 1997, 7, 350-354.	2.5	0
139	OncoLink: A Cancer Information Resource for Gynecologic Oncologists and the Public on the Internet. <i>Gynecologic Oncology</i> , 1996, 60, 8-15.	1.4	20
140	Surgically Documented Responses to Paclitaxel and Cisplatin in Patients with Primary Peritoneal Carcinoma. <i>Gynecologic Oncology</i> , 1996, 62, 55-58.	1.4	22
141	Expression of A, B, and H Blood Group Antigens in Epithelial Ovarian Cancer: Relationship to Tumor Grade and Patient Survival. <i>Gynecologic Oncology</i> , 1996, 62, 106-112.	1.4	24
142	Arterial Occlusion Complicating Treatment of Gynecologic Cancer: A Case Series. <i>Gynecologic Oncology</i> , 1996, 63, 40-46.	1.4	21
143	Racial differences in survival from gynecologic cancer. <i>Obstetrics and Gynecology</i> , 1996, 88, 914-918.	2.4	55
144	Adenovirus-mediated gene therapy of ovarian cancer in a mouse model. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 175, 1260-1265.	1.3	27

#	ARTICLE	IF	CITATIONS
145	Expression and mutational analysis of P53 in stage IB and IIA cervical cancers. American Journal of Obstetrics and Gynecology, 1996, 175, 1266-1271.	1.3	18
146	Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of <i>BRCA1</i> . New England Journal of Medicine, 1996, 335, 1413-1416.	27.0	408
147	Advances in surgery for gynecologic malignancies. Current Opinion in Oncology, 1995, 7, 473-477.	2.4	4
148	Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer, 1995, 75, 2700-2705.	4.1	57
149	Secondary cytoreduction in epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 1995, 18, 1-8.	4.4	14
150	The Accuracy of a Frozen Section Diagnosis of Borderline Ovarian Malignancy. Gynecologic Oncology, 1995, 59, 183-185.	1.4	74
151	Cytoreductive Surgery in Ovarian Carcinoma Patients with a Documented Previously Complete Surgical Response. Gynecologic Oncology, 1995, 57, 61-65.	1.4	132
152	The Effect of Renal Function on Serum Levels of CA 125. Gynecologic Oncology, 1995, 58, 375-377.	1.4	18
153	Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer, 1994, 73, 1456-1459.	4.1	69
154	Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer, 1994, 73, 1882-1888.	4.1	156
155	Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer, 1993, 71, 1565-1570.	4.1	46
156	Monoclonal antibodies in the management of ovarian cancer: A clinical perspective. Cancer, 1993, 71, 1602-1612.	4.1	20
157	High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. British Journal of Haematology, 1993, 83, 433-441.	2.5	95
158	Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity. Journal of Cancer Research and Clinical Oncology, 1993, 119, 360-362.	2.5	13
159	Phase II trial of zeniplatin (CL 286 558), a new platinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy. Journal of Cancer Research and Clinical Oncology, 1993, 119, 234-236.	2.5	7
160	High-Resolution Positron Emission Tomography of Human Ovarian Cancer in Nude Rats Using ¹²⁴ I-Labeled Monoclonal Antibodies. Gynecologic Oncology, 1993, 48, 61-67.	1.4	21
161	Evidence for Persistence of Mitoxantrone within the Peritoneal Cavity Following Intraperitoneal Delivery. Gynecologic Oncology, 1993, 48, 185-188.	1.4	8
162	The Use of Recombinant Human Erythropoietin to Prevent Carboplatin-Induced Anemia. Gynecologic Oncology, 1993, 49, 172-176.	1.4	33

#	ARTICLE	IF	CITATIONS
163	Salvage Intraperitoneal Mitoxantrone Therapy of Ovarian Cancer: Influence of Increasing the Volume of Treatment. <i>Gynecologic Oncology</i> , 1993, 49, 185-189.	1.4	7
164	Impact of Age on Survival of Patients with Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 49, 236-239.	1.4	43
165	Mitomycin-C Plus a 3-Day Continuous Intravenous Infusion of 5-Fluorouracil: An Inactive Salvage Regimen for Platinum-Resistant Ovarian Carcinoma. <i>Gynecologic Oncology</i> , 1993, 50, 30-33.	1.4	1
166	Comparison of Antigen Expression on Fresh and Cultured Ascites Cells and on Solid Tumors of Patients with Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 78-83.	1.4	24
167	Evidence Supporting the Superiority of Intraperitoneal Cisplatin Compared to Intraperitoneal Carboplatin for Salvage Therapy of Small-Volume Residual Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 50, 100-104.	1.4	75
168	Biodistribution and Intraoperative Evaluation of Radiolabeled Monoclonal Antibody MX 35 in Patients with Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 51, 61-66.	1.4	28
169	Secondary Cytoreduction—Thoughts on the "Pro" Side. <i>Gynecologic Oncology</i> , 1993, 51, 127-130.	1.4	5
170	Limited-Field Radiotherapy as Salvage Treatment of Localized Persistent or Recurrent Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , 1993, 51, 349-354.	1.4	17
171	Early Invasive Carcinoma of the Cervix. <i>Gynecologic Oncology</i> , 1993, 51, 26-32.	1.4	53
172	Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. <i>American Journal of Obstetrics and Gynecology</i> , 1993, 168, 162-169.	1.3	119
173	Isoflurane versus fentanyl: hemodynamic effects in cancer patients treated with anthracyclines. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1993, 7, 307-311.	1.3	13
174	Surgery for gynecologic malignancies. <i>Current Opinion in Oncology</i> , 1992, 4, 923-929.	2.4	3
175	Rapid Delivery of Multiple High-Dose Chemotherapy Courses With Granulocyte Colony-Stimulating Factor and Peripheral Blood-Derived Hematopoietic Progenitor Cells. <i>Journal of the National Cancer Institute</i> , 1992, 84, 1935-1936.	6.3	36
176	Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1992, 47, 353-357.	1.4	17
177	Endoluminal ultrasound staging of cervical cancer. <i>Gynecologic Oncology</i> , 1992, 46, 186-190.	1.4	10
178	Resection of pulmonary metastases from uterine sarcomas. <i>Gynecologic Oncology</i> , 1992, 45, 202-205.	1.4	122
179	Management of vulvar melanoma. <i>Gynecologic Oncology</i> , 1992, 45, 254-258.	1.4	111
180	Characterization of a human endometrial carcinoma cell line producing intraperitoneal tumor growth in immunodeficient mice. <i>Gynecologic Oncology</i> , 1992, 45, 273-278.	1.4	7

#	ARTICLE	IF	CITATIONS
181	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. <i>Gynecologic Oncology</i> , 1992, 45, 284-289.	1.4	151
182	Management of endometrial adenocarcinoma with cervical involvement. <i>Gynecologic Oncology</i> , 1992, 45, 294-298.	1.4	33
183	Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1485-1491.	1.6	295
184	Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1479-1484.	1.6	81
185	Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.. <i>Journal of Clinical Oncology</i> , 1992, 10, 243-248.	1.6	124
186	Surgery for Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 1992, 6, 851-865.	2.2	11
187	Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 163-165.	2.5	12
188	Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 119, 55-57.	2.5	54
189	Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 391-394.	2.5	3
190	Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992, 118, 235-237.	2.5	7
191	Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1991, 164, 558-563.	1.3	19
192	Extended-field radiation therapy in early-stage cervical carcinoma: Survival and complications. <i>Gynecologic Oncology</i> , 1991, 43, 51-54.	1.4	46
193	Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy. <i>Gynecologic Oncology</i> , 1991, 43, 159-163.	1.4	17
194	Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy. <i>Gynecologic Oncology</i> , 1991, 40, 17-20.	1.4	14
195	Intraperitoneal chemotherapy: Analysis of complications with an implanted subcutaneous port and catheter system. <i>Gynecologic Oncology</i> , 1991, 41, 101-106.	1.4	62
196	Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma. <i>Gynecologic Oncology</i> , 1991, 41, 217-219.	1.4	7
197	Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 1991, 42, 137-141.	1.4	111
198	Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube. <i>Gynecologic Oncology</i> , 1991, 42, 156-160.	1.4	41

#	ARTICLE	IF	CITATIONS
199	Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.. Journal of Clinical Oncology, 1991, 9, 1801-1805.	1.6	178
200	Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.. Journal of Clinical Oncology, 1991, 9, 978-982.	1.6	31
201	Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.. Journal of Clinical Oncology, 1991, 9, 204-210.	1.6	47
202	Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.. Journal of Clinical Oncology, 1991, 9, 389-393.	1.6	781
203	Celiac Axis and Superior Mesenteric Artery Injury Associated with Left Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma. Journal of Urology, 1991, 146, 1104-1107.	0.4	20
204	Paget's Disease of the Vulva. Obstetrical and Gynecological Survey, 1991, 46, 387.	0.4	0
205	Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. Journal of Cancer Research and Clinical Oncology, 1991, 117, 89-90.	2.5	30
206	Palliative Surgery for Intestinal Obstruction in Advanced Ovarian Cancer. Obstetrical and Gynecological Survey, 1990, 45, 73-74.	0.4	0
207	Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy for ovarian cancer.. Journal of Consulting and Clinical Psychology, 1990, 58, 153-157.	2.0	67
208	Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.. Journal of Clinical Oncology, 1990, 8, 146-150.	1.6	70
209	Immunohistochemical localization of P-glycoprotein in adult human ovary and female genital tract of patients with benign gynecological conditions.. Journal of Histochemistry and Cytochemistry, 1990, 38, 1677-1681.	2.5	27
210	Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. American Journal of Obstetrics and Gynecology, 1990, 163, 69-73.	1.3	33
211	Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecologic Oncology, 1990, 38, 358-363.	1.4	32
212	Treatment of endometrial stromal tumors. Gynecologic Oncology, 1990, 36, 60-65.	1.4	160
213	Paget's disease of the vulva. Gynecologic Oncology, 1990, 39, 374-377.	1.4	122
214	Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.. Journal of Clinical Oncology, 1989, 7, 1327-1332.	1.6	86
215	Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecologic Oncology, 1989, 34, 16-19.	1.4	114
216	Intestinal surgery in gynecologic oncology. Gynecologic Oncology, 1989, 34, 30-33.	1.4	27

#	ARTICLE	IF	CITATIONS
217	Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 353-356.	1.4	6
218	Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 1989, 34, 365-371.	1.4	121
219	A longitudinal study of antigen expression in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1989, 34, 389-394.	1.4	16
220	Long-term access to the peritoneal cavity in ovarian cancer patients. <i>Gynecologic Oncology</i> , 1989, 33, 46-48.	1.4	23
221	Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 1989, 160, 667-671.	1.3	100
222	Second-look surgery in ovarian carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 1988, 8, 75-91.	4.4	31
223	Ovarian Cancer. <i>AORN Journal</i> , 1988, 47, 1427-1437.	0.3	0
224	Recurrence after negative second-look laparotomy for ovarian cancer: Analysis of risk factors. <i>American Journal of Obstetrics and Gynecology</i> , 1988, 159, 1094-1098.	1.3	79
225	Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.. <i>Journal of Clinical Oncology</i> , 1988, 6, 158-162.	1.6	14
226	A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 1988, 6, 689-695.	1.6	55
227	Postmenopausal Bleeding: Etiology, Evaluation, and Management. <i>Medical Clinics of North America</i> , 1987, 71, 59-69.	2.5	12
228	Radical hysterectomy for recurrent cervical cancer following radiation therapy. <i>Gynecologic Oncology</i> , 1987, 27, 316-322.	1.4	32
229	Well-differentiated adenocarcinoma of endometrium with simple karyotypic changes: A case report. <i>Cancer Genetics and Cytogenetics</i> , 1987, 25, 21-26.	1.0	22
230	Lymph node nomenclature in gynecologic oncology. <i>Gynecologic Oncology</i> , 1986, 23, 222-226.	1.4	19
231	Endometrial Curettage at the Time of Cervical Conization. <i>Obstetrics and Gynecology</i> , 1986, 67, 663-664.	2.4	3
232	Tumor Antigens in Ovarian Malignancy. <i>Clinical Obstetrics and Gynecology</i> , 1986, 29, 693-704.	1.1	10
233	Squamous carcinoma of the vagina: Treatment, complications and long-term follow-up. <i>Gynecologic Oncology</i> , 1985, 20, 346-353.	1.4	85
234	Para-aortic nodal metastases in early cervical carcinoma: Long-term survival following extended-field radiotherapy. <i>Gynecologic Oncology</i> , 1984, 18, 213-217.	1.4	41

#	ARTICLE	IF	CITATIONS
235	Paraaortic nodal metastases in early cervical carcinoma: Long-term survival following extended field radiotherapy. <i>Gynecologic Oncology</i> , 1983, 15, 139.	1.4	0
236	Serum fucose as a monitor for recurrent malignancy. <i>Journal of Surgical Oncology</i> , 1978, 10, 39-44.	1.7	10